fashion -WSS

fashion

author：leisure time 2025-09-27 10:01:59 - browse：7856

Zepbound, a injectable drug on a gradient background of dark purple and green — biotech coverage from STAT — Illustration: STAT; Source: Eli Lilly/AP

Eli Lilly’s blockbuster diabetes and obesity drug improved living scarring in a mid-stage study of the liver disease MASH, adding to positive data announced earlier this year.

The study tested three doses of tirzepatide, sold commercially as Mounjaro or Zepbound. The percentage of patients who experienced a greater than one-stage improvement in scarring, or fibrosis, without worsening of their disease was 54.9%, 51.3%, and 51.0% from the lowest to highest doses.

When compared with the 29.7% of patients on placebo who achieved this outcome, the results were statistically significant, according to an abstract of data that will be presented at the annual meeting of the European Association for the Study of the Liver.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Virginia high school admissions case could be legal follow
Next article： Type 2 diabetes prevention programs work at large scale: study

WSS

Medical school prerequisites are outdated

Ohio still needs to do more to protect the right to abortion

Experimental asthma app from Apple and Anthem shows promise

Medical device trials still don't enroll enough women, study finds

Study suggests Covid rebound is far more common with Paxlovid than without

Eli Lilly’s chief scientist on obesity drugs, gene editing, and more

explore

fashion

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Wikipedia

The high cost of giving birth even with insurance

Study suggests Covid rebound is far more common with Paxlovid than without

Indiana Supreme Court upholds abortion ban, says state constitution gives only limited protections

Moderna says combo Covid

Malaria cases in Florida and Texas: Here’s what you need to know

Coercive sterilizations revealed by STAT prompt outrage

Sports medicine is finally prioritizing gender equality

Publishing genetic code of viruses could cause disaster

Alkermes shareholders re

Publishing genetic code of viruses could cause disaster

leisure time

UnitedHealth sued over use of algorithm in Medicare Advantage plans

Lilly's Alzheimer's drug donanemab backed by FDA advisers

How the BIOSECURE Act is already affecting U.S., Chinese life science firms

Readout LOUD Podcast: Lilly's obesity drug, the power of radiation

First transplant of an entire human eye performed

Eli Lilly’s chief scientist on obesity drugs, gene editing, and more

focus

focus

Wikipedia

explore